7Baggers

We provide you with 20 years of free, institutional-grade data for TSHA stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of TSHA. Explore the full financial landscape of TSHA stock.

Reported DateCIKTickerType
2025-08-121806310TSHA10-QUrl
2025-05-151806310TSHA10-QUrl
2025-02-261806310TSHA10-KUrl
2024-11-131806310TSHA10-QUrl
2024-08-121806310TSHA10-QUrl
2024-05-141806310TSHA10-QUrl
2024-03-191806310TSHA10-KUrl
2023-11-141806310TSHA10-QUrl
2023-08-141806310TSHA10-QUrl
2023-05-111806310TSHA10-QUrl
2023-03-281806310TSHA10-KUrl
2022-11-081806310TSHA10-QUrl
2022-08-111806310TSHA10-QUrl
2022-05-161806310TSHA10-QUrl
2022-03-311806310TSHA10-KUrl
2021-11-101806310TSHA10-QUrl
2021-08-161806310TSHA10-QUrl
2021-05-111806310TSHA10-QUrl
2021-03-031806310TSHA10-KUrl
2020-11-121806310TSHA10-QUrl
2020-09-021806310TSHAS-1Url

Taysha Gene Therapies, Inc
(NASDAQ:TSHA) 

TSHA stock logo

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the t...

Founded: 2019
CEO: R. A. Session  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
The information provided in this report about TSHA stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.